PRESSEMITTEILUNGEN

Barcelona, Spain (ots/PRNewswire) – - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins

New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers.

Many of the existing statins such as atorvastatin and simvastatin are metabolised by cytochromes, particularly CYP3A4, and inhibitors of this pathway such as itraconazole and grapefruit juice can increase plasma concentrations of the statins. Taking one of these statins with a CYP3A4 inhibitor can increase the risk of a patient being hospitalised with severe muscle problems six-fold.(2) Administration of atorvastatin with itraconazole can increase atorvastatin plasma concentrations 2.5-3.3 times normal and even certain foods, like grapefruit juice can increase plasma concentrations by 80%.(3)

Previous studies with pitavastatin show that grapefruit juice does not have a significant effect on plasma concentrations (concentrations increased by

Trackback URL

Atorvastatin, Barcelona Spain, Cyp3a4 Inhibitors, Drug To Drug Interaction, European Society Of Cardiology, European Society Of Cardiology Congress, Grapefruit Juice, Hospitalised, Itraconazole, Muscle Problems, Pathway, Pharmacokinetics, Pitavastatin, Plasma Concentrations, Prnewswire, Relevant Effect, Simvastatin, Statins, Volunteers